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Intra-articular injection (IAI) of steroid is a safe and effective treatment for painful
knee osteoarthritis (OA).1 The mechanism of action is thought to be partly mediated
by an anti-inflammatory effect on the synovium which may be detected by changes
observed on ultrasound (US) examination.2 Placebo IAI of saline can also
significantly reduce pain though the mechanisms are not generally thought to
associate with a peripheral effect.3-5 This pilot study aimed to investigate whether
improved knee pain correlated with improved US measures following IAI of a
corticosteroid or a placebo in OA knees.
Twenty-five participants with painful knee OA (Kellgren & Lawrence grade >2) were
randomised to one of two treatment sequences (IAI of methylprednisolone (40mg in
1 ml) followed by IAI of saline placebo (1ml, 0.9%), or vice versa) to their most
painful knee. 1 ml of synovial fluid (equal to the volume injected) was aspirated from
the knee joint. No participant had inflammatory arthritis or had IAI of steroid within
the previous 3 months. The 2nd injection was delivered after knee pain returned to its
pre-injection level. Pain was assessed using a 100mm visual analogue scale (VAS)
and Western Ontario and McMaster Osteoarthritis Knee Index (WOMAC).6 US
examination was carried out by a blinded assessor immediately prior to and 1 week
following each injection, using a Toshiba Aplio SSA-770A machine with a multi-
frequency (7-12 MHz) linear array transducer. A standardised protocol reflecting
EULAR and OMERACT definitions was used.7,8 Maximal depth of effusion, synovial
hypertrophy and popliteal cysts were measured in millimeters (mm).
Ten men and fifteen women (mean age, 72 years (SD 7.8)) were enrolled and
completed the study. All baseline characteristics were balanced for both sequence
groups (p<0.05). Independent t-tests showed no order effect for pain response
following the steroid injection (p=0.87) or placebo injection (p=0.72) and there was
no significant difference in the mean time (days) between injections (steroid first = 95
(SD 65); placebo first = 81 (SD 47); p=0.81).
As expected, significant improvements in pain VAS were observed following both
injections (mean difference: steroid -17.4mm SD (26.8), p=0.003; placebo -13.44mm
SD (22.44), p=0.006) (table 1, figure 1A). Maximal depth of synovial hypertrophy was
significantly reduced following the steroid injection (mean difference -0.94mm SD
(2.18), p=0.04) and was non-significantly reduced following the placebo injection
(mean difference -0.98mm SD (3.65) p=0.91) (table 1, figure 1B). No change in
effusions (table 1, figure 1C) or popliteal cysts were observed following either
injection (table 1). We found no correlation between change in pain VAS and change
in US measures following either injection though this may be related to the small
sample size.
The observed improvement in synovial hypertrophy following IAI of steroid accords
with a recent MRI study which reported a significant reduction in mean synovial
volume following IAI of steroid.9 However, we also observed a reduction in synovial
hypertrophy following the placebo injection which mirrored the changes following the
steroid. The analgesic effects of a placebo are considered to occur through
expectancy-induced descending inhibitory mechanisms such as release of
endogenous opioid but it has also been suggested that a reduction of local
inflammation may arise through activation of the hypothalamic-pituitary-adrenal
(HPA) axis as part of expectancy-induced descending inhibition of pain.10 We
believe that this may be the first study to show a possible peripheral (“anti-
inflammatory”) effect of IAI of placebo on the synovium, whilst acknowledging that
our observations may partly reflect natural variances in synovial hypertrophy.
Properly powered studies are needed to confirm these findings.
Contributors MH, PC, KL, WZ and MD conceived the study. SD performed the US
examination. MH and WZ analysed the data. MH, WZ and MD drafted the
manuscript, PC and KL contributed to revising the manuscript.
Funding We are grateful to Arthritis Research UK for funding this work (AHP
Training Fellowship Grant no. 18861).
Competing interests None.
Ethics approval Derbyshire Research Ethic Committee approved this study.
Patient consent Obtained.
Provenance and peer review Not commissioned; externally peer-reviewed.
Table 1 Pain and ultrasound measures at baseline and change at 1 week following
intra-articular cortico-steroid and placebo injection.
Baseline Change at 1 week
Placebo
N=25
Steroid
N=25
†P value Placebo
N=25
‡P value
(for
placebo)
Steroid
N=25
‡P value
(for
steroid)
†P
value
Pain VAS (mm) 61.8(20.5) 61.4(22.2) 0.95 -13.4 (22.4) 0.006 -17.4 (26.8) 0.003 0.59
WOMAC
Pain (0-20) 9.2 (3.5) 9.4 (2.7) 0.82 -0.8 (2.4) 0.11 -2.0 (2.7) 0.001 0.13
Stiffness (0-8) 3.9 (1.7) 3.9 (1.2) 1.00 -0.3 (1.3) 0.30 -0.6 (1.5) 0.30 0.43
Function (0-58) 33.4(11.2) 32.3(10.3) 0.70 -1.4 (6.6) 0.30 -2.6 (8.4) 0.14 0.61
US Features (mm)
Effusion 7.3 (3.6) 7.0 (3.9) 0.76 -0.6 (2.5) 0.28 -0.1 (2.5) 0.91 0.40
Synovial hypertrophy 7.7 (4.5) 6.9 (3.6) 0.50 -1.0 (3.7) 0.19 -0.9 (2.2) 0.04 0.91
Popliteal cyst
median (range) 0 (0-10.8) 0 (0-14.20) 0.70 0 (-3.1, 6.1) 0.69 0 (-9.8, 4.4) 0.11 0.12
VAS, Visual analogue scale; WOMAC, Western Ontario and McMaster Osteoarthritis Knee Index; US
Ultrasound.
Data are presented as mean (SD) where normally distributed and as the median (range) where non-
normally distributed.
†P values represent paired tests for differences between placebo and steroid injections
‡P values represent paired tests for change from baseline to 1 week
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